Aod 9604 vs Semaglutide
Which Is Right for You? Complete Comparison (2026)
AOD-9604 vs Semaglutide comparison — HGH fragment 176-191 that directly stimulates lipolysis vs GLP-1 receptor agonist that reduces appetite centrally.
Aod 9604 vs Semaglutide: At a Glance
- ✓Modified HGH fragment (amino acids 176-191)
- ✓Stimulates lipolysis (fat breakdown) in adipose tissue
- ✓Inhibits lipogenesis (new fat formation)
- ✓Does not affect blood glucose or IGF-1 levels
- ✓Does not promote growth or cell proliferation
- ✓GLP-1 receptor agonist — targets satiety pathways
- ✓Reduces appetite via hypothalamic signalling
- ✓Slows gastric emptying → prolonged fullness
- ✓~15% body weight loss in STEP trials (Wegovy 2.4 mg)
- ✓FDA-approved for obesity (Wegovy) and T2D (Ozempic)
Detailed Comparison
| Feature | Aod 9604 | Semaglutide |
|---|---|---|
| Mechanism | HGH fragment peptide (lipolytic) | GLP-1 receptor agonistBest |
| Dosing | 250-500 mcg SC daily (typically morning fasted) | Ozempic: 0.25-2 mg/week SC; Wegovy: up to 2.4 mg/week SC |
| Administration | Subcutaneous injection | Subcutaneous injection weekly (or oral: Rybelsus) |
| Half-life | ~30 minutes | ~7 days |
| FDA Status | Not FDA-approved — TGA (Australia) approved as food supplement | FDA-approved (Ozempic for T2D, Wegovy for obesity) |
| Key Trial | Heffernan MA et al. Endocrinology 2001 — lipolytic activity in obese mice | Wilding JPH et al. NEJM 2021 (STEP 1) — 14.9% weight loss |
| Side Effects | Injection site reactions, headache — generally well-tolerated | Nausea, vomiting, diarrhea, constipation (dose-dependent GI effects) |
Which Should You Choose?
AOD-9604 (hgh fragment peptide (lipolytic)) and Semaglutide (glp-1 receptor agonist) target different aspects of health despite overlapping interest areas. AOD-9604 modified fragment (amino acids 176-191) of human growth hormone that stimulates lipolysis and inhibits lipogenesis without affecting blood sugar or growth. Semaglutide synthetic glp-1 analogue that activates glp-1 receptors to reduce appetite, slow gastric emptying, and improve glycemic control.
Whichever you choose, track your protocol in Shotlee to build clean data for dose optimization and outcomes comparison.
Making an Informed Choice Between Aod 9604 and Semaglutide
Choosing between Aod 9604 and Semaglutide depends on multiple individual factors including your specific health goals, tolerance profile, insurance coverage, and prescriber recommendation. While clinical trial data provides population-level efficacy and safety comparisons, your personal response may differ based on genetics, baseline health, concurrent conditions, and lifestyle factors. Use this comparison as a starting framework and discuss the specifics with your healthcare provider.
Head-to-head clinical trial data between Aod 9604 and Semaglutide is the gold standard for comparison, but such direct comparisons are not always available for every pair of compounds. Where head-to-head data is lacking, cross-trial comparisons provide useful but imperfect approximations — differences in patient populations, trial design, and endpoint definitions mean that numbers from separate trials are not directly interchangeable. Keep this context in mind when evaluating the comparison data presented here.
Tracking your personal response data in Shotlee is particularly valuable when switching between medications or considering a change. By documenting your outcomes on your current protocol — including efficacy metrics, side effect profile, adherence rate, and quality of life measures — you create an objective baseline for comparison if you transition to the alternative compound. This data transforms a subjective switching decision into an evidence-based protocol optimization.
Aod 9604 vs Semaglutide: Frequently Asked Questions
AOD-9604 is a hgh fragment peptide (lipolytic) while Semaglutide is a glp-1 receptor agonist. They differ in mechanism, dosing, and clinical evidence. Your choice should depend on your specific goals and medical history.
Switching should be done under medical supervision. Your prescriber can advise on transition protocols. Track both in Shotlee for comparison data.
AOD-9604 works as a hgh fragment peptide (lipolytic) (250-500 mcg SC daily (typically morning fasted)), while Semaglutide is a glp-1 receptor agonist (Ozempic: 0.25-2 mg/week SC; Wegovy: up to 2.4 mg/week SC). They have different half-lives (~30 minutes vs ~7 days), side effect profiles, and levels of clinical evidence.
Yes. Shotlee supports tracking any medication or peptide. You can compare your results across different protocols.
Neither is universally better — the right choice depends on your individual health profile, treatment goals, side effect tolerance, insurance coverage, and prescriber recommendation. Clinical trial data shows efficacy differences in specific populations, but personal response varies. Track your experience with either medication in Shotlee to generate objective comparison data with your healthcare provider.
Switching between these medications should be done under medical supervision. Your prescriber will consider factors including your current response, reason for switching, dose equivalence, and transition timing. Use Shotlee to document your outcomes on the current medication so you have a clear baseline for comparison after switching.
Track Aod 9604 or Semaglutide in Shotlee
Free dose tracking, side effect logging, and outcome comparison for any medication protocol.